Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2005 June;140(3) > Giornale Italiano di Dermatologia e Venereologia 2005 June;140(3):237-47

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014


eTOC

 

REVIEWS  


Giornale Italiano di Dermatologia e Venereologia 2005 June;140(3):237-47

Copyright © 2005 EDIZIONI MINERVA MEDICA

language: English

Oral medications for psoriasis

Cather J. C. 1,2

1 Texas Dermatology Research Institute, Dallas, TX, USA
2 Clinic Baylor University Medical Center, Dallas, TX, USA


PDF  


Several oral medications have been used to treat psoriasis. Systemic medications are indicated for the treatment of psoriasis refractory to topical medications, associated with a decreased quality of life, or moderate to severe in nature (large body surface area involved >10%, erythrodermic, or pustular). Additionally, psoriatic arthritis requires systemic therapy. Only the tumor necrosis factor antagonists prevent the progression of joint disease and therefore a shift in the treatment paradigm from traditional oral medications to newer biologic agents (etanercept, infliximab, or adalimumab) for this indication is in practice. This article will review the more commonly used traditional oral medications used for the treatment of psoriasis with emphasis on appropriate patient selection, monitoring, and combination therapies.

top of page

Publication History

Cite this article as

Corresponding author e-mail